Blood sugar control and a GLP-1 medicine's effect on islet GLP-1 in people with type 1 or type 2 diabetes
Official title: The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People
Run by Mayo Clinic · NCT06976619 · Data updated 2026-11-12
We will test whether tighter blood sugar control and a GLP-1 drug (liraglutide) change islet GLP-1 in people with type 1 or type 2 diabetes who use insulin.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 25 Years to 70 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Status | Recruiting |
| Started | October 3, 2025 |
| Main results expected | October 30, 2028 |
| Study ends | March 31, 2029 |
| Registry record updated | October 19, 2026 |
| Trial ID | NCT06976619 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 25–70 with type 1 or type 2 diabetes who are treated with insulin, have HbA1c ≤10%, no major abdominal surgery history, and no GLP-1 receptor agonist use in the past year are ideal candidates.
✕Probably not a fit
People who are younger than 25 or older than 70, pregnant, have active systemic illness or malignancy, symptomatic macro- or microvascular disease, or recent GLP-1 use are unlikely to qualify or benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 2 interventional study will compare the effects of improved glycemic control with or without a GLP-1 receptor agonist (liraglutide) on islet GLP-1 production in people with insulin-treated type 1 and type 2 diabetes. Participants will receive liraglutide injections or saline while glycemic control is managed, and investigators will measure islet-related GLP-1 signals and related insulin and glucagon responses. The design tests whether presence or absence of functional beta cells (T2DM vs T1DM) changes the islet response to GLP-1 agonism. All procedures and visits are conducted at a single center with laboratory and metabolic assessments to characterize paracrine islet effects.
Why it matters
Potential benefit: If successful, this work could identify ways to modulate islet hormone signaling that may improve insulin and glucagon regulation and inform new treatments for diabetes.
How similar studies have gone: Related animal and human studies have shown islet GLP-1 signaling and effects of GLP1R blockade, but using GLP-1 agonists to differentially target islet GLP-1 in T1 versus T2 diabetes is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Type 1 or type 2 diabetes treated with insulin Exclusion Criteria: 1. Age \< 25 or \> 70 years. 2. HbA1c \> 10.0% 3. For female subjects: positive pregnancy test at the time of enrollment or study 4. History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy. 5. Prior use of GLP-1 receptor agonists in the previous year. 6. Active systemic illness or malignancy. 7. Symptomatic macrovascular or microvascular disease.
Where it's running
-
Mayo Clinic in Rochester
Rochester, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Adrian Vella, MD — Mayo Clinic
- Study coordinator: Adrian Vella, MD
- Email: vella.adrian@mayo.edu
- Phone: 507-255-6515
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Next Generation Extended Wear Sensors in Type 1 and Type 2 Diabetes
This study tests a new extended wear sensor and algorithm in people with type 1 or type 2 diabetes to see how well it works across adults and children.
-
NOURISH: a community partnership to improve nutrition and glycemic control in pregnant women with pregestational diabetes
Aiming to test a healthcare-community program that delivers healthy food weekly and provides nutrition education to pregnant women with type 1 or type 2 diabetes who have food insecurity, to improve blood sugar and pregnancy outcomes.
-
Permissive versus strict blood sugar control during labor for pregnant people with type 1 diabetes
This trial will test whether allowing slightly higher blood sugars (70–140 mg/dL) during labor is as safe for newborns as keeping tighter control (70–110 mg/dL) for pregnant people with type 1 diabetes using hybrid closed‑loop insulin systems.
-
Evaluation of a dosing guidance system for diabetes management
This study is testing a new system that helps people with Type 1 and Type 2 diabetes manage their insulin doses better to see if it improves their blood sugar control.
-
Investigating mortality and cardiovascular diseases in adults with type 1 diabetes
This study looks at how type 1 diabetes affects the risk of dying and heart problems in adults compared to those with type 2 diabetes and people without diabetes.
-
Nationwide registry of pregnancies in women with diabetes
This study is trying to gather information about pregnancies in women with diabetes to see how their health and their babies' health are affected, and to find better ways to support them during and after pregnancy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.